Key statistics
As of last trade Elanco Animal Health Inc (ELAN:NYQ) traded at 25.12, -3.66% below its 52-week high of 26.08, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 25.02 |
|---|---|
| High | 25.27 |
| Low | 25.02 |
| Bid | 25.10 |
| Offer | 25.14 |
| Previous close | 25.13 |
| Average volume | 4.56m |
|---|---|
| Shares outstanding | 496.86m |
| Free float | 491.54m |
| P/E (TTM) | 350.88 |
| Market cap | 12.49bn USD |
| EPS (TTM) | 0.0716 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 14:48 GMT.
More ▼
Press releases
- Elanco Announces Updates to Board of Directors
- Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
- Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
- Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
- Elanco Investor Day Defines New Era as Sustainable Growth Company
- Elanco executive appointed as Neurizon's Board Observer
- Elanco executive appointed as Neurizon's Board Observer
- Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
- Elanco to Participate in the Upcoming Investor Conferences
More ▼
